CLINICAL EVALUATION AND SATISFACTION OF PATIENTS TREATED WITH PRGF-ENDORET (Plasma Rich in Growth Factors)

Abstrac number 4CPS-148
Pharmacy Service, Hospital Arnau de Vilanova, Valencia

BACKGROUND

PRGF-Endoret is an autologous preparation obtained from the patient's own blood containing a set of proteins specifically addressed to wound healing and tissue regeneration of the ocular surface. It is used to treat dry eye, often displacing other therapies such as autologous serum.

The **objective** of this study is to evaluate the efficacy and safety of PRGF-Endoret eye drops, as well as patient satisfaction, in patients with dry eyes.

MATERIAL AND METHODS

Retrospective observational study of all patients for whom PRGF-Endoret was requested between February 2019 and October 2019, for the treatment of several disorders with ocular dryness as a symptom.

Demographic and clinical data obtained from the electronic medical history

- **Age**
- **Gender**
- **Diagnosis**
- **Indication**
- **Dosage**
- **Treatment start date**
- **Treatment duration**
- **Previous treatment**
- **Clinical evolution**

In addition, two anonymous surveys were conducted based on the Dry Eye Questionnaire (DEQ). **First survey** in patients who started treatment, evaluating the frequency of several symptoms: eye dryness, foreign body sensation, eye stinging, pain, eye tingling, blurred vision, eye redness, discomfort to light. **Second survey** when renewing the treatment, evaluating the efficacy and safety (taking as measure the appearance of adverse effects) and also the satisfaction with the treatment.

RESULTS

- **N = 22**
- **SEX**
  - 14 (64%)
  - 8 (36%)
- **Median age of 64 (24-95)**

According to the electronic medical history in 73% of cases the clinical evolution was favorable in at least three months, requesting treatment renewal in 68%. Only one case reported insomnia as possible adverse effect. Three patients (14%) have not yet completed three months of treatment.

The results of the surveys indicate that 100% of patients were satisfied and noticed improvement in several symptoms. 50% of patients had previously received autologous serum, 82% of them had a favorable evolution (2 without evaluation).

CONCLUSION

The results indicate that PRGF-Endoret improves dry eye symptoms in our patients and is safe, and patients were satisfied. Patients previously treated with autologous serum had favourable evolution with PRGF-Endoret. Although it is supposed to be more expensive, patients were satisfied with the change.